However, in patients with HER2-positive breast cancer with BM, the KAMILLA trial, which studied patients with advanced HER2-positive breast cancer, also included BM patients with untreated and asymptomatic or previously irradiated and controlled disease. This evidence concerns the gene ERBB2 and breast cancer.